BioCentury | Feb 13, 2012
Clinical News

ATS907: Phase IIa started

...patients, while the second stage will compare ATS907 vs. latanoprost in up to 180 patients. Altheos...
...develop and commercialize ATS907 for all indications from Asahi Kasei (see BioCentury, April 12, 2010). Altheos Inc....
BioCentury | Feb 13, 2012
Financial News

Altheos financial update

...the round to $32.5 million. Altheos raised $20 million in the round in April 2010. Altheos Inc....
BioCentury | Feb 10, 2012
Financial News

Altheos raises $12.5M, starts glaucoma trial

...by Bay City Capital, Novo A/S and Canaan Partners. ATS907 is a Rho kinase inhibitor. Altheos...
BioCentury | Oct 4, 2010
Company News

Altheos management update

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Hired: Barbara Wirostko as CMO, formerly senior medical director and glaucoma medical team lead at Pfizer Inc. WIR Staff Ophthalmic...
BioCentury | Apr 12, 2010
Company News

Altheos, Asahi Kasei Pharma deal

...Asahi Kasei granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907...
...Rho kinase inhibitors to treat glaucoma and other ophthalmic indications. Financial terms were not disclosed. Altheos Inc....
BioCentury | Apr 12, 2010
Company News

Altheos board of directors update

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Appointed: Lester Kaplan, a member of Bay City Capital's scientific advisory board, as chairman; Peter Bisgaard of Novo A/S; Rob Hopfner of Bay City Capital; and Wende...
BioCentury | Apr 12, 2010
Financial News

Altheos completes venture financing

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Date completed: 4/5/10 Type: Venture financing Raised: $20 million Investors: Bay City Capital; Novo A/S; Canaan Partners; Life Science Angels Inc.; Atheneos Capital WIR Staff Ophthalmic...
BioCentury | Apr 12, 2010
Strategy

Altheos Mines its Rho-lodex

...interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc....
...secure rights to what they believe to be best-in-class topical Rho kinase inhibitors for glaucoma. Altheos...
...the compounds, according to President and CSO M. (Ken) Kengatharan. Kengatharan and CEO Henry Hsu, Altheos'...
BioCentury | Apr 6, 2010
Financial News

Altheos raises $20M, in-licenses glaucoma compound

...A round on Monday and announced a deal with Asahi Kasei Pharma Corp. Asahi granted Altheos...
...Partners; Life Science Angels; and Atheneos Capital also participated. Bay City's Lester Kaplan will join Altheos'...
...Bay City's Rob Hopfner, Novo's Peter Bisgaard and Canaan's Wende Hutton also joining the board. Altheos...
Items per page:
1 - 9 of 9
BioCentury | Feb 13, 2012
Clinical News

ATS907: Phase IIa started

...patients, while the second stage will compare ATS907 vs. latanoprost in up to 180 patients. Altheos...
...develop and commercialize ATS907 for all indications from Asahi Kasei (see BioCentury, April 12, 2010). Altheos Inc....
BioCentury | Feb 13, 2012
Financial News

Altheos financial update

...the round to $32.5 million. Altheos raised $20 million in the round in April 2010. Altheos Inc....
BioCentury | Feb 10, 2012
Financial News

Altheos raises $12.5M, starts glaucoma trial

...by Bay City Capital, Novo A/S and Canaan Partners. ATS907 is a Rho kinase inhibitor. Altheos...
BioCentury | Oct 4, 2010
Company News

Altheos management update

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Hired: Barbara Wirostko as CMO, formerly senior medical director and glaucoma medical team lead at Pfizer Inc. WIR Staff Ophthalmic...
BioCentury | Apr 12, 2010
Company News

Altheos, Asahi Kasei Pharma deal

...Asahi Kasei granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907...
...Rho kinase inhibitors to treat glaucoma and other ophthalmic indications. Financial terms were not disclosed. Altheos Inc....
BioCentury | Apr 12, 2010
Company News

Altheos board of directors update

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Appointed: Lester Kaplan, a member of Bay City Capital's scientific advisory board, as chairman; Peter Bisgaard of Novo A/S; Rob Hopfner of Bay City Capital; and Wende...
BioCentury | Apr 12, 2010
Financial News

Altheos completes venture financing

Altheos Inc. , South San Francisco, Calif. Business: Ophthalmic Date completed: 4/5/10 Type: Venture financing Raised: $20 million Investors: Bay City Capital; Novo A/S; Canaan Partners; Life Science Angels Inc.; Atheneos Capital WIR Staff Ophthalmic...
BioCentury | Apr 12, 2010
Strategy

Altheos Mines its Rho-lodex

...interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc....
...secure rights to what they believe to be best-in-class topical Rho kinase inhibitors for glaucoma. Altheos...
...the compounds, according to President and CSO M. (Ken) Kengatharan. Kengatharan and CEO Henry Hsu, Altheos'...
BioCentury | Apr 6, 2010
Financial News

Altheos raises $20M, in-licenses glaucoma compound

...A round on Monday and announced a deal with Asahi Kasei Pharma Corp. Asahi granted Altheos...
...Partners; Life Science Angels; and Atheneos Capital also participated. Bay City's Lester Kaplan will join Altheos'...
...Bay City's Rob Hopfner, Novo's Peter Bisgaard and Canaan's Wende Hutton also joining the board. Altheos...
Items per page:
1 - 9 of 9